Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), PepGen Inc. (PEPG) and RegenXBio (RGNX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on OptimizeRx (OPRX – Research Report), PepGen Inc. (PEPG – Research Report) and RegenXBio (RGNX – Research Report) with bullish sentiments.

OptimizeRx (OPRX)

RBC Capital analyst Sean Dodge maintained a Buy rating on OptimizeRx yesterday and set a price target of $17.00. The company’s shares closed last Tuesday at $10.48.

According to TipRanks.com, Dodge has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.3% and a 38.3% success rate. Dodge covers the Healthcare sector, focusing on stocks such as Privia Health Group, Healthcare Services, and Avid Bioservices.

Currently, the analyst consensus on OptimizeRx is a Strong Buy with an average price target of $16.33, which is a 51.9% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $16.00 price target.

See today’s best-performing stocks on TipRanks >>

PepGen Inc. (PEPG)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on PepGen Inc. today and set a price target of $26.00. The company’s shares closed last Tuesday at $13.99.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 12.8% and a 49.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Zentalis Pharmaceuticals.

Currently, the analyst consensus on PepGen Inc. is a Strong Buy with an average price target of $22.25.

RegenXBio (RGNX)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on RegenXBio today and set a price target of $38.00. The company’s shares closed last Tuesday at $15.80.

According to TipRanks.com, Chen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.4% and a 27.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as OKYO Pharma Limited Sponsored ADR, Bausch + Lomb Corporation, and Barinthus Biotherapeutics.

Currently, the analyst consensus on RegenXBio is a Strong Buy with an average price target of $38.50, which is a 142.3% upside from current levels. In a report issued on May 8, RBC Capital also maintained a Buy rating on the stock with a $35.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OPRX:

• OptimizeRx to Participate in Upcoming Investor Conferences 
• OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET
• OptimizeRx sees Q1 revenue $18.5M-$19.2M, consensus $17.03M
• OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report
• Navigating New Horizons: Optimizerx Corporation’s Strategic Pivot Raises Financial Risk Flags